Product Images Pemetrexed

This is a description of Pemetrexed for Injection, a cytotoxic agent that should only be used via an intravenous route. Each single-dose vial contains 1000mg of pemetrexed disodium and 1000mg of manitol, as well as adjustments made with hydrochloric acid or sodium hydroxide to adjust pH. Storage should be kept between 20C to 25C, and the literature should be consulted before the drug is given. This drug is manufactured by Glnd Parma I in India and is intended for use in OncoPoint.*

This is a product description for Pemetrexed for Injection, USP, a cytotoxic agent used for intravenous use only. The medication comes in a single-use vial containing 1000mg/vial. To prepare for use, it needs to be reconstituted with 40mL of 0.9% Sodium Chloride USP injection. The solution needs to be further diluted before use per accompanying instructions. Once reconstituted, the solution should be used within 24 hours and any unused portion should be discarded. Dosage and administration information should be obtained from prescribing information. The medication should be stored between 20°C-25°C and should be protected from excursions of 15°C to 30°C. The product is manufactured in India.*

It seems to be a survival probability chart, with survival time in months as the x-axis and survival probability as the y-axis. The text seems to be showing the survival probability for different time periods, with decreasing probabilities as the time increases.*

The text appears to be a table of data with headings "Gometabin + Clpi (60)", "J — Pametece Clspain )", and "Patients at Risk". The other columns contain numerical data, possibly related to survival time or medical treatment. However, without more context or information it is difficult to interpret or explain the significance of this data.*

This appears to be a graph or chart displaying data related to survival probability. The "Survival Time" is measured in months and is shown on the bottom axis. The "Survival Probability" is shown on the vertical axis. The graph includes a curved line that likely represents the probability of survival over time. There are also some numerical values listed on the graph, but their meaning is unclear without additional context.*

The text is describing a survival probability chart comparing the outcomes of two groups, Pometocea and Placebo. The chart displays the number of patients at risk for each group, the survival time in months, and the corresponding survival probability. However, due to the errors and inconsistencies, the information presented is not clear and may not be reliable.*

This is a table showing the survival probability of patients under treatment with Pematrexed and placebo. The number of patients at risk is shown in each row. It is not possible to interpret the purpose of the "aw", "2" and "108" values as they are incomplete.*